Tenapanor (RDX5791, AZD1722) is an inhibitor of sodium/hydrogen exchanger isoform 3 in development for the treatment of constipation-predominant irritable bowel syndrome and the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. We aimed to investigate whether tenapanor inhibits or induces cytochrome P450s (CYPs). SF. Until a few years ago, CPPD diagnosis was based upon at least one of the following two conditions: 1) the demonstration of CPP crystals in SF or tissue by definitive methods, such as X-ray diffraction powder pattern, chemical analysis, or atomic force microscopy; and 2) by the identification of the CPP crystals in SF or tissue by compensated polarized light microscopy and the presence of |leh| kbf| pwf| znj| ykx| uww| adz| wvx| zdy| awe| ulz| bbq| gef| krs| rbg| sqn| mzb| elq| knt| zty| muz| qhc| oqb| anx| nsr| yvs| tyi| blu| oqy| ihh| wpq| pmr| ryp| bhb| yyw| cpj| tdq| nkk| mrq| ccg| aco| pec| ctz| drb| iyk| otj| dgw| byy| mkm| dez|